RBC
VRTX icon

Romano Brothers & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Romano Brothers & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-266
Closed -$76.8K – 969
2022
Q4 		$76.8K Buy
+266
New +$81.1K 0.01% 404

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Romano Brothers & Co's VRTX Position: Q1 2023 in Review

Romano Brothers & Co sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 266 shares — an estimated $76.8K sold.

Romano Brothers & Co first reported a position in VRTX in Q4 2022 and held it in 1 quarter. The position peaked at $76.8K in Q4 2022. 1,207 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

  • Romano Brothers & Co reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Romano Brothers & Co sold 266 Vertex Pharmaceuticals shares in Q1 2023, an estimated $76.8K.
  • Romano Brothers & Co first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Romano Brothers & Co's Vertex Pharmaceuticals position peaked at $76.8K in Q4 2022.
  • 1,207 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.